Approving Psychedelics
The organization formed... as a public-benefit corporation, in anticipation that MDMA-assisted therapy would win FDA approval and start to reap taxable revenue that it couldn’t manage as a nonprofit.
Select Page
by C. Scott McMillin | May 13, 2024 | Addictive Substances | 0 |
The organization formed... as a public-benefit corporation, in anticipation that MDMA-assisted therapy would win FDA approval and start to reap taxable revenue that it couldn’t manage as a nonprofit.
by C. Scott McMillin | Jan 25, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 11, 2024 | In the News | 0 |
by C. Scott McMillin | Dec 21, 2023 | Addictive Substances | 0 |
by C. Scott McMillin | Nov 27, 2023 | Addictive Substances | 0 |
by C. Scott McMillin | Nov 9, 2023 | Addictive Substances | 0 |
by C. Scott McMillin | Sep 14, 2023 | Addictive Substances | 0 |
All that free positive publicity has surely been a great help to the emerging psychedelic industry and the elements in the financial community who are rushing to exploit it.
Read Moreby C. Scott McMillin | Jul 13, 2023 | Addictive Substances | 0 |
In 1961, two Harvard students ended up in the mental hospital after consuming psilocybin…” Not long afterwards, Harvard lost much of its enthusiasm for the (psilocybin research) program.
Read Moreby C. Scott McMillin | Jun 1, 2023 | Addictive Substances | 0 |
Because studies also suggest some real risks. Dangers, in fact. It’s possible that the current wave of fawning reports of miraculous cures could be replaced by stories of horrific incidents.
Read Moreby C. Scott McMillin | May 22, 2023 | Addictive Substances | 0 |
Antidepressant benefits that are almost immediate but wear off over time. From a patient’s perspective, that could be a real drawback, especially in view of how costly the treatments might have been.
Read Moreby C. Scott McMillin | Apr 24, 2023 | Addictive Substances, In the News | 0 |
When the trip ends, the writer acknowledges, the user may be “…throwing up or having trouble at the other end.”
Read Moreby C. Scott McMillin | Apr 20, 2023 | Addictive Substances, In the News | 0 |
Also, one of the local rags had a few Shroom House products tested and discovered, to no one’s surprise, that some had been made from synthetics. Not the ‘real thing’, after all.
Read Moreby C. Scott McMillin | Mar 6, 2023 | Addictive Substances | 0 |
If 25% of patients in studies either 1) didn’t benefit or 2) had a negative experience, perhaps even a terrifying one– that’s a lot.
Read Moreby C. Scott McMillin | Jan 5, 2023 | Addictive Substances | 0 |
Easy to see how given the right combination of circumstances, it could be wiped out in a relatively short period.
Read Moreby C. Scott McMillin | Dec 5, 2022 | Resources | 0 |
“As we say with most things you come across in a national park, whether it be a banana slug, unfamiliar mushroom, or a large toad with glowing eyes in the dead of night, please refrain from licking…”
Read Moreby C. Scott McMillin | Nov 21, 2022 | Addictive Substances, In the News | 0 |
The idea is to get into the market early, grab as much share as you can, so that when the inevitable shakeout occurs, and smaller vendors drop out, you’re left in the catbird seat.
Read Moreby C. Scott McMillin | Sep 1, 2022 | Thinking About Addiction | 0 |
…where the NFL and the solons of pro sports may be waiting on the results of the clinical trials and approval from FDA before they proceed, those same young fans are more likely to just go ahead and buy the stuff off the friend of a friend and, you know, take it.
Read More